Federal regulators have filed a federal lawsuit against digital health company Hims & Hers, alleging widespread consumer deception regarding privacy practices, subscription billing methods, and product cancellation hurdles. The Federal Trade Commission, joined by attorneys general from Utah and California, announced the legal action following an extensive investigation into the direct-to-consumer telehealth provider’s business operations.
According to the regulatory complaint, Hims allegedly misled customers regarding the sharing of confidential medical information with major technology platforms including Meta and Snap. Regulators also stated that the platform failed to adequately disclose that completing an online medical intake questionnaire automatically enrolled users in a recurring, auto-renewing subscription for pharmaceuticals.
The enforcement action highlights growing scrutiny by federal and state regulators over digital health platforms, consumer data privacy, and recurring subscription models. As online healthcare options expand, agencies are increasingly targeting practices that obscure billing terms or share personal health data without explicit, informed consent.
Federal Lawsuit Alleges Data Sharing and Hidden Subscription Charges
The federal complaint outlines multiple points of friction between company practices and regulatory standards. Regulators assert that patients navigating the site encountered virtually no opportunity to review independent provider treatment recommendations before incurring financial charges. Furthermore, the lawsuit claims the platform erected unnecessary barriers for users attempting to cancel ongoing medication shipments.
Data privacy forms a central pillar of the government’s case. The filing alleges that consumer health data—gathered during sensitive medical evaluations—was transmitted to third-party advertising networks. Such disclosures, according to the filing, occurred without the transparent disclosure or explicit authorization required under state and federal consumer protection frameworks.
Company Response and Defense Strategy
Representatives for Hims & Hers pushed back sharply against the allegations, issuing a public response via the social media platform X. The company defended its operations and criticized the timing and nature of the regulatory filing.
“This lawsuit disregards substantial evidence we provided the FTC during its nearly three-year investigation, ignores established state laws and industry standards in telehealth, and contorts the law to try to manufacture claims,” the company stated on X. The statement added, “This is not enforcement grounded in consumer protection; it is an effort to generate headlines at our expense. We are confident in our position and will vigorously defend ourselves against these baseless claims.”
Broader Implications for Telehealth Providers
The case represents a significant milestone in regulatory enforcement within the direct-to-consumer digital medicine sector. Over recent years, federal agencies have heightened their focus on how telehealth applications handle user data, particularly concerning pixels and tracking tools embedded in web interfaces. Companies operating in this space face heightened compliance expectations regarding clear subscription disclosures and rigorous data governance.
Readers seeking further updates can monitor official regulatory databases, including announcements from the Federal Trade Commission, for subsequent court filings and scheduling orders.